

PROVIDER QUICK POINTS

PROVIDER INFORMATION



December 15, 2016

Pharmacy Step Therapy Program Name Change for Anticonvulsant Agents and Update on Drugs Subject to This Step Therapy Program

Effective January 1, 2017, Blue Cross and Blue Shield of Minnesota (Blue Cross) is renaming the Anticonvulsant Agents Step Therapy (ST) Criteria to Fibromyalgia Agents Step Therapy. With the renaming of the ST program, there are anticonvulsant drugs that will no longer be subject to ST. The ST program will continue to allow use of Lyrica when the patient has had prior use of generic duloxetine, amitriptyline, nortriptyline, desipramine, imipramine, gabapentin, cyclobenzaprine, or tramadol. In addition, the program will continue to accommodate use of Lyrica for the treatment of seizure disorders.

Renamed Pharmacy Step Therapy Program Name	Drug Name
Fibromyalgia Agents ST	Lyrica® (pregabalin)
Drugs No Longer Subject to Anticonvulsant Agents ST and Will Not Be Subject to Fibromyalgia Agents ST	Briviact® (brivaracetam) Keppra® (levetiracetam) Keppra XR® (levetiracetam ER) Lamictal® (lamotrigine) Lamictal ODT® (lamotrigine) Lamictal XR® (lamotrigine ER) Oxtellar XR® (oxcarbazepine XR) Potiga® (ezogabine) Qudexy™ XR (topiramate ER) Spritam® (levetiracetam) Topamax® (topiramate) Topiramate ER (topiramate ER) Trileptal® (oxcarbazepine) Trokendi XR™ (topiramate ER) Vimpat® (lacosamide)

Products impacted

This notice applies to commercial lines of business.

The new Pharmacy ST program will be posted by January 1, 2017, and can be accessed using the Blue Cross provider link.

- Access **providers.bluecrossmn.com**
- Under Tools And Resources, select Medical policy, then acknowledge the Acceptance statement
- Select Utilization Management
- Select Pharmacy Utilization Management Programs

QP42-16

Distribution: Available on providers.bluecrossmn.com. <https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications>

CoverMyMeds for step therapy request service

As a reminder, CoverMyMeds (CMM) is a free service to providers which allows quick and easy submission of ST requests. Experience with CMM by other plans has demonstrated marked reductions in physician office call-backs regarding ST requests, after CMM is implemented. ST requests may also continue to be faxed to their review destination external to the CMM portal, as is the current practice.

You may access CMM at www.covermymeds.com. Select Help (top right of the web page) to view FAQs and Support tutorials (3-5 minutes), including live online chat support to help you get started. You will need to open a CMM account to submit requests using the portal.

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.